Philip is an experienced entrepreneur and CEO who has founded and headed several companies in various industries. He has a passion for transforming early-stage technologies into breakthrough products. He co-founded Ovizio Imaging Systems and holds several director positions. He’s President of the Board of Aenitis (Paris) and has a background in engineering and an MBA from ESCP Business School.

Cédric Van Nevel has a strong interest in new and upcoming technologies and the impact they can generate on our society and daily life. He started his career as a strategic consultant at Boston Consulting Group before building further experience in the energy sector through a number of management positions at Fluxys (ranging from M&A to construction). Prior to joining Qbic, Cédric was responsible for the venturing activities of Bekaert, actively scouting for relevant technologies, setting up collaborations and holding a number of advisory board positions in international funds. He holds an MSc in Electronics from the University of Ghent.

Jan is the founder of Novalis Biotech Incubation, and a serial entrepreneur in the food and biotech industry. Following his education in bio-engineering, he worked as senior consultant for the Boston Consulting Group and as an independent strategy consultant. Jan co-founded and served as director of Genohm, which was acquired by Agilent Technologies in 2018. Jan also served as director and chairman of Oystershell laboratories, a world-class developer of innovative consumer healthcare products. The company was acquired by Gilde Buy-Out Partners in 2017. Jan is co-owner and director of Lipa Holding, a family business in food and recycling, and is operating partner in Victus Participations, an independent agri and food growth investment fund. Jan obtained an MBA from INSEAD, and a Master in General Management from Vlerick Management School.

Patrick is an independent investor in several startups in medtech and other technologies. He is also chairman of Xeos Medical and Animab and board member at Clouds of Care. He was the Chief executive officer at the Nuscience group and is still chairman of Pegasus.

Daisy Flamez is an experienced business developer with strong ties to Ghent University. Her business development work has included the IOF consortium BIOMARKED and the Cancer Research Institute of Ghent (CRIG). She is also a partner in NXTGNT, the University of Ghent Center of Excellence in pharmacoepigenomics. In addition to her business background, she has a doctorate in biotechnology and molecular biology.

Stefaan has been a professor at Ghent University since 1999 and is a world-renowned expert on advanced drug delivery. Currently he is the pro-dean of the Faculty of Pharmaceutical Sciences, and the director of the Ghent Research Group on Nanomedicines.

Marie-Pierre Rols is currently Research Director at the IPBS-CNRS laboratory in Toulouse, France, and head of the “Cellular Biophysics” group. Her main research interests are in the field of membrane destabilization by pulsed electric fields leading to electropermeabilization of cells and tissues. She is involved in various aspects such as the elucidation of the mechanisms of cell electroporation and DNA electrotransfer.

Pascale has more than 20 years of commercial and business development experience within the biotechnology industry. Her scientific background is in molecular and cellular biology. She worked for FujiFilm Regenerative Medicine and for TreeFrog Therapeutics where she initiated the Japan and US based business partnerships with biotech and Pharma companies. Possessing a strong curiosity-based mindset as the foundation for all projects involving new technologies and the people behind them.

Wilfred Germeraad is Associate professor of Immunology at the Department of Internal Medicine at Maastricht University, the Netherlands. He is also co-founder and CSO of CiMaas BV, a biotech company developing cellular immunotherapy for cancer that was created as spin-off from Maastricht University. His research focuses on developing NK cell therapy for acute myeloid leukemia and bringing that to clinical applications in the GMP manufacturing facility of CiMaas. Further research into combination treatments of combination therapies with antibodies or CAR-NK cells is under development and include applications in solid tumors.

Prof. Heinz Redl is a leader in trauma research and tissue regeneration, co-directs the SHoW research group at Vienna’s Ludwig Boltzmann Institute for Traumatology. With over 600 publications and 15 patents, his work has revolutionized trauma care. He coordinates the Austrian Cluster for Tissue Regeneration, organizes conferences, and holds prestigious awards and fellowships. Dr. Redl’s expertise spans trauma diagnostics, therapeutics, and musculoskeletal tissue regeneration, driving innovations that reshape medical possibilities globally.